Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
Several immune and metabolic dysregulations in SLE and PsA patients are described, which could be used as potential biomarkers for disease progression and therapeutic intervention.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by systemic chronic inflammation that can lead to heterogeneous clinical manifestations, from mild cutaneous disease to multi-organ damage and failure. Understanding how immune cell composition, their activation status, and metabolic changes contribute to disease is important to identify new biomarkers and therapeutic targets.
In this study, we combined spectral flow cytometry and CITE-Seq to profile immune cell subsets and metabolic changes at the single-cell level. Peripheral white blood cells from SLE patients, psoriatic arthritis (PsA) patients, and healthy donors were analyzed using a 50-marker panel that evaluated immune subsets, activation and exhaustion markers, including metabolic dependencies by using SCENITH. The same antibody panel was used in CITE-Seq to validate flow cytometric findings and explore additional metabolic and inflammation pathways. High-dimensional computational analysis was used to identify immune subpopulations with specific metabolic signatures that distinguished SLE from PsA and healthy individuals.
Across 44 immune cell populations, we observed significant immunophenotypic and immunometabolic changes in both diseases. B cell analysis revealed altered frequencies, different translational activity, and metabolic dependence in early developmental and antigen-experienced cell subsets. SCENITH profiling showed distinct metabolic signatures in CD4+ and CD8+ T cells, with more pronounced differences in naive and memory subsets. In fact, in SLE, T cells exhibited strong dependence on OXPHOS and limited sensitivity to glycolytic inhibition. Finally, PsA patients presented increased NKT-cell frequencies, indicating an involvement of lipid antigens.
Overall, these findings describe several immune and metabolic dysregulations in SLE and PsA patients, which could be used as potential biomarkers for disease progression and therapeutic intervention.
Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) project 321115009 (GRK 2336/3)
Basic Autoimmunity (BA)
Abstract Objective Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by substantial variability in clinical presentations and disease severity. This study aims to investigate the molecular and cellular mechanisms underlying distinct SLE Disease Activity Index (SLEDAI)-defined disease stat...
Chen Shen, Ming-Zhe Guo, Jian Huang et al.· Lupus Science and Medicine· 0 citations
OBJECTIVES
Systemic sclerosis (SSc) is a progressive autoimmune disease in which pathogenic processes may begin before clinical onset. We aimed to characterise molecular alterations across the spectrum from the asymptomatic SSc-specific autoantibody-positive (SSAP) phase through very early diagnosis of SSc (VEDOSS) to...
Feng-Lin Wu, Zhang-Yi Zhao, Wan-Yi Lin et al.· Annals of the Rheumatic Dise...· 0 citations
Objectives Autoimmune diseases such as primary Sjögren’s disease (pSjD) and systemic lupus erythematosus (SLE) share clinical and serological features, including type I interferon signatures, autoantibody formation, and chronic inflammation, but the underlying immunopathology is not the same. To support the development...
F. Szelinski, Ana-Luisa Stefanski, A. Wiedemann et al.· Frontiers in Immunology· 0 citations
While smoking cessation must likely be absolute to reverse pathogenic trafficking signals (such as GPR15 upregulation), the linear effect of BMI suggests that incremental weight loss confers proportional immunologic benefits, which strongly support the integration of lifestyle interventions as a core component of early...
Simon Falk, A. Schulte-Mecklenbeck, P. Ostkamp et al.· Neurology(R) neuroimmunology...· 0 citations
BACKGROUND
Lupus arthritis (LA) is a major determinant of clinical outcomes and treat-to-target strategies in systemic lupus erythematosus (SLE), yet its molecular basis remains elusive.
METHODS
Whole-blood RNA sequencing from 170 SLE [67 with active arthritis but quiescent disease in other organs; 42 with only mucoc...
G. Sentis, C. Kalantzi, S. Flouda et al.· Journal of Autoimmunity· 0 citations
OBJECTIVE
Systemic lupus erythematosus (SLE) is an autoimmune disease closely associated with enzyme dysfunction, yet its underlying molecular mechanisms remain incompletely understood. This study aims to characterize enzyme-network alterations associated with SLE status and disease activity and to identify candidate m...